Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 1.00 |
| ▸ | HRH1 | P35367 | 17/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040987 | 0.94 | HTR6 (0.88) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL8035210 | 0.91 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL8031143 | 0.88 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL1224355 | 0.88 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3715129 | 0.87 | HTR6 (0.79) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL13696219 | 0.87 | HTR6 (0.87) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL4139227 | 0.87 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL8031098 | 0.85 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL12882032 | 0.85 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL8021887 | 0.85 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009082268-A2 | LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | ALLA CHEM, LLC (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ADRB3, ADRA2C, ADRB2 | HTR6 40/4885HRH1 19/4885ADRA2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.